Mark L. Pacala Acquires 90,562 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala bought 90,562 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average price of $1.04 per share, with a total value of $94,184.48. Following the transaction, the director now directly owns 224,971 shares of the company’s stock, valued at $233,969.84. This represents a 67.38 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Oncology Institute Trading Up 2.7 %

Shares of TOI opened at $1.14 on Friday. The firm has a market cap of $86.14 million, a P/E ratio of -1.46 and a beta of 0.41. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The Oncology Institute, Inc. has a 1 year low of $0.13 and a 1 year high of $1.63. The company has a 50 day simple moving average of $0.86 and a two-hundred day simple moving average of $0.48.

Oncology Institute (NASDAQ:TOI) last posted its earnings results on Monday, March 24th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The company had revenue of $100.27 million for the quarter, compared to analysts’ expectations of $109.15 million. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%.

Institutional Investors Weigh In On Oncology Institute

A number of hedge funds have recently made changes to their positions in the company. HighTower Advisors LLC grew its holdings in Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after buying an additional 53,382 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Oncology Institute by 613.6% during the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after acquiring an additional 109,769 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Oncology Institute in the fourth quarter valued at $41,000. Renaissance Technologies LLC increased its position in Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after purchasing an additional 12,000 shares during the last quarter. Finally, FreeGulliver LLC raised its stake in Oncology Institute by 219.3% during the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock valued at $186,000 after purchasing an additional 412,578 shares in the last quarter. 36.86% of the stock is currently owned by hedge funds and other institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.